Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost...
Transcript of Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost...
![Page 1: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/1.jpg)
Le terapie cellulari post allotrapianto
Mar0no Introna, MD
USC Ematologia, USS Centro di Terapia Cellulare «G.
Lanzani», ASST Papa Giovanni XXIII, Bergamo
![Page 2: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/2.jpg)
• Nothing in biology makes sense except in the light of evolu7on (1973)
• Theodosius Dobzansky (1900-‐1975)
![Page 3: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/3.jpg)
Other an0gens or naive
![Page 4: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/4.jpg)
Adapted from Bollard C. et al, Blood, 2017
Nonspecific T cell
![Page 5: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/5.jpg)
Tzannou I. et al, Immunotherapy, 2015
A: Manufacturing procedure for genera7ng AdV, EBV and CMV-‐specific VSTs. Ad5f35pp65: Adeniviral vector encoding for the CMV an7gen pp65; EBV-‐LCLs: EBV transformed lymphoblastoid cell lines; Tri-‐VSTs: an7-‐AdV, CMV and EBV. B: Genera7ng Pentavalent VSTs. AdV: Adenovirus; BKV:BK virus; HHV-‐6: Human herpesvirus 6; VST: Virus-‐specific T cell.
Genera7on of ex vivo expanded virus-‐specific T cells
![Page 6: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/6.jpg)
A total of 32 lines were produced and characterized, 18 of which were administered to the 50 study pa7ents (Baylor College, Houston, Texas, US). The selec7on of lines for infusion was based on the specificity of the line for the target virus through a shared HLA allele, as well as the overall level of HLA match.
Banked third-‐party vst to treat severe viral infec7ons
Leen A. et al, Blood, 2013
![Page 7: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/7.jpg)
Leen A. et al, Blood, 2013
Banked third-‐party VST to treat severe viral infec7ons
Infec7on cohort AdV (n=18) CMV (n=23) EBV (n=9) Total (n=50)
![Page 8: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/8.jpg)
Leen A. et al, Blood, 2013
Banked third-‐party VST to treat severe viral infec7ons
![Page 9: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/9.jpg)
Leen A. et al, Blood, 2013
Banked third-‐party VST to treat severe viral infec7ons
![Page 10: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/10.jpg)
Melenhorst J. et al, Blood, 2010
Banked third-‐party vst to treat severe viral infec7ons Allogeneic virus-‐specific T cells with HLA alloreac7vity do not produce GVHD in human subjects
The authors reviewed their clinical experience with adop7ve transfer of allogeneic HSCT donor derived virus specific CTLs in 153 recipients, including 73 where there was an HLA mismatch.
![Page 11: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/11.jpg)
![Page 12: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/12.jpg)
15 well-‐selected New Zealand donors could cover 57% of the Scobsh pa7ent popula7on. This rose to 85% with 25 donors. 25–50 x 109 mononuclear cells (MNCs) were collected from each of 25 donors into 10 bags by apheresis, cryopreserved in 10% dimethyl sulfoxide (DMSO), then shipped to the UK in vapour phase liquid nitrogen (Scobsh Na7onal Blood Transfusion Service)..
Vickers M. et al, Bri7sh Journal of Haematology, 2014
EBV specific banks to treat EBV associated lymphoprolifera7ve disease
![Page 13: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/13.jpg)
Vickers M. et al, Bri7sh Journal of Haematology, 2014
Human leucocyte an7gen matching of donors with recipients. The number of matches at five human leucocyte an7gen (HLA) loci are shown as histograms of the best matched prospec7ve recipient–donor pairs. Matches that resulted in cytotoxic T lymphocyte infusions are shown in grey, those that did not in black. For two pairs, informa7on was only available at HLA class I.
EBV specific banks to treat EBV associated lymphoprolifera7ve disease
![Page 14: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/14.jpg)
Bollard C. et al, Journal of Clinical Oncology, 2014
Type II or III EBV posi7ve lymphoma treated with autologus LMP CTL Frequency of LMP specific and tumor an7gen specific T cells
![Page 15: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/15.jpg)
Bollard C. et al, Journal of Clinical Oncology, 2014
Type II or III EBV posi7ve lymphoma treated with autologus LMP CTL Evidence for epitope spreading in 12 pa7ents with lymphoma
![Page 16: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/16.jpg)
Melenhorst J. et al, Molecular Therapy, 2015
GVL without GVH by Mul7virus specific T cells
12 yrs boy with RR-‐ALL haplotransplanted from the mother
![Page 17: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/17.jpg)
Melenhorst J. et al, Molecular Therapy, 2015
GVL without GVH by Mul7virus specific T cells
![Page 18: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/18.jpg)
Meij P. et al, Haematologica, 2012
Three pa7ents were treated with HA-‐1-‐specific T-‐cell lines. Aier infusion, no toxicity was observed, showing that administra7on of these T-‐cell lines was safe. Although in one pa7ent, during a period of stable disease, HA-‐1-‐specific T cells could be detected in the peripheral blood and bone marrow, no clear clinical response occurred in these pa7ents.
Genera7on and administra7on of HA-‐1-‐specific T-‐cell lines for the treatment of pa7ents with relapsed leukemia aier allogeneic stem cell transplanta7on
![Page 19: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/19.jpg)
Lulla P. et al, Blood, 2017
![Page 20: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/20.jpg)
Comoli P. et al, Blood, 2017
BCR-‐ABL–specific T-‐cell therapy in Ph1 ALL pa7ents on tyrosine-‐kinase inhibitors
![Page 21: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/21.jpg)
Cornelis A.M. et al, JCI, 2017
Selec7ve GVL depends on magnitude and diversity of the alloreac7ve T cell response: frequencies of alloreac7ve T cells
Absolute numbers of iden7fied alloreac7ve T cells clones are depicted on top of the bars.
![Page 22: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/22.jpg)
Ghimire S. et al, Fron7ers in Immunology, 2017
![Page 23: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/23.jpg)
Kolb H. et al, Transplanta7on, 1997
Adop7ve immunotherapy in canine chimeras
![Page 24: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/24.jpg)
Ramos C. et al, Annual Review of Medicine, 2017
Basic structure of first genera7on chimeric an7gen receptors (CAR)s
![Page 25: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/25.jpg)
EBV reac7va7on and immune responses in pa7ent 7. Detec7on of EBV-‐DNA viral load by Q-‐PCR (light gray squares), CD19.CAR transgene by Q-‐PCR (black circles), and EBV-‐specific T-‐cell responses (striped bars) by IFNg ELISpot in the PB are illustrated. Arrows denote 7me of CD19.CAR-‐VSTs infusions. This pa7ent is described in complete response aier 8 months follow up.
Cruz C. et al, Blood, 2013
Donor derived CD19 (CAR) redirected VST for B-‐cell malignancies relapsed aier allo BMT
![Page 26: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/26.jpg)
TCR
MHC I
Target cell
Tumor cell
++
CIK cell Restricted killing
Non MHC-‐restricted killing
CD3/CD8/CD56 T/EMRA
DNAM1 LFA1
CD56 NKG2D NKp30
Adapted by Pievani et al, Blood, 2011
![Page 27: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/27.jpg)
Phase II study: Clinical Response
N %
Total evaluable pa0ents 73
Complete remission 19 26
Par0al remission 3 4
Stable disease 8 11
Progression of disease 41 56
Early death 2 3
22 (30%) response
Introna M. et al, submiked
![Page 28: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/28.jpg)
Phase II study: Toxicity
Grade N pa0ents (%) N insurgence during or a_er DLI treatment
N insurgence during or a_er CIK treatment
aGvHD 1-‐2 7 (9) 5 2
3-‐4 5 (7) 3 2
cGvHD*
Mild 4 (5) 0 4
Moderate 5 (7) 0 5
Severe 2 (3) 1 1
Hemoli0c Anemia
N.A. 1 (2) 0 1
Introna M. et al, submiked
![Page 29: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/29.jpg)
Phase II study: PFS and OS
Introna M. et al, submiked
![Page 30: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/30.jpg)
Isola0on of PBMC
D0
Electropora0on
SB11X tansposase
CAR-‐encoding SB transposon
CD123-‐CAR Chimeric receptor
CD28
OX-‐40
ζ -‐ Chain
Expansion with IL-‐2 D21
Engineered CIK cells
CD123-‐CAR+
CD123-‐CAR+ CIK cells specific targe0ng
HSPCs
AML cells
CD123
Rambaldi et al, Leukemia, 2015
![Page 31: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/31.jpg)
Kill
Tumor cell CIK
Bispecific an0body
Target Effector
![Page 32: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/32.jpg)
Adapted from Ramos C. et al, Annual Review of Medicine, 2017
CIK
![Page 33: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/33.jpg)
Pardoll D. et al, Nature Reviews Cancer, 2012
![Page 34: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/34.jpg)
• L’immunità è perfekamente capace di combakere le infezioni e cos7tuisce un esempio di risposta adaka7va a una for7ssima pressione selebva (morte precoce).
• L’immunità non è perfekamente capace di combakere i tumori perché ques7 non sono una forza selebva, insorgendo, per lo più, dopo la generazione dei figli.
• Forse si possono immaginare strategie terapeu7che cellulari di combinazione (massimizzando gli effeb (GVL+GVI) e riducendo la tossicità (GVH).
![Page 35: Leterapiecellularipost allotrapianto - ER Congressi · 2017. 6. 12. · Leterapiecellularipost allotrapianto # Mar0no#Introna,#MD# # USCEmatologia,USSCentrodiTerapiaCellulare«G.](https://reader035.fdocuments.in/reader035/viewer/2022071012/5fcb020882c42410f30eda8d/html5/thumbnails/35.jpg)
USC Hematology, ASST Papa Giovanni XXIII, Bergamo PI: Prof. A. Rambaldi F. Lussana A. Algarob C. Micò A. Grassi G. Grib
USS Centro di Terapia Cellulare «G. Lanzani»,
ASST Papa Giovanni XXIII, Bergamo
J. Golay RAQ C. Capelli O.Pedrini E. Gob R. Valgardsdobr S. Mar7nelli A. Interdonato F. Corren7 M. Introna QP
Clinical Trial Unit F. Delaini M. L. Ferrari C. Pavoni M. Magri
Div. Hematology and TMO, Bolzano, Italy, Dr. I. Cavakoni, Dr. S. Deola Department of Pediatrics, University of Milano-‐Bicocca, Fondazione MBBM, Monza, Italy, Prof. E. Biagi, Dr. A. Balduzzi, Dr. A. Rovelli, Dr. S. Napolitano, Dr. G. Sgroi, Dr. E. Marrocco, Prof. A. Biondi Department of Hematology, Monza, Italy, Dr. M. Parma; Apheresis Unit, Monza, Italy, Dr. P. Perseghin; Laboratory of Cell and Gene Therapy “S. Verri”, Monza, Italy, Dr. G. Gaipa, Dr. D. Belob, Dr. B. Cabia7